Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Analysis of the Evolution of SUVmax by Quantitative Analysis Method of Bisphosphonate Scintigraphy for the Follow-up of Patients With Transthyretin Amyloidosis Treated With Tafamidis

NCT04849754 is registered in ClinicalTrials.gov with GCS Ramsay Santé pour l'Enseignement et la Recherche as lead sponsor.

NCT NCT04849754
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04849754 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Analysis of the Evolution of SUVmax by Quantitative Analysis Method of Bisphosphonate Scintigraphy for the Follow-up of Patients With Transthyretin Amyloidosis Treated With Tafamidis
Lead sponsor
GCS Ramsay Santé pour l'Enseignement et la Recherche
Phase
Not applicable
Overall status
Recruiting
Start date
February 25, 2021
Completion date
December 31, 2026
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiac amyloidosis